Wishing you all the joys of the season! 
Asia Pacific Molecular Diagnostics for Infectious Disease Market Forecast to 2030
Asia Pacific Molecular Diagnostics for Infectious Disease Market Forecast to 2030 – Regional Analysis – by Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Mononucleosis, Group A Streptococcus (GAS), and Others) and Laboratory Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)]
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Advancements in Molecular Diagnostics Technologies Fuels the Asia Pacific Molecular Diagnostics for Infectious Disease Market
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
Asia Pacific Molecular Diagnostics for Infectious Disease Market Overview
The molecular diagnostics for infectious disease market in Asia Pacific is subsegmented into Malaysia, Thailand, India, Singapore, the Philippines, Vietnam, Indonesia, China, Japan, Australia, South Korea, and the Rest of Asia Pacific. Rising geriatric population; increasing infectious diseases; growing research activities and technological advancements; and surging number of startups, biotechnology, and biopharmaceutical companies are the factors favoring the market progress in this region. Moreover, the presence of associations or organizations enhancing the quality of care in infectious disease management contributes to the molecular diagnostics for infectious disease market growth. According to a blog published by ChinaTown Online, ~1 in 7 people from the age range of 15-49 has been infected with sexually transmitted diseases (STDs) in China. Chlamydia, gonorrhea, genital warts, and syphilis are the most common STDs. According to the WHO, ~370 million new cases of trichomoniasis, Neisseria gonorrhea (NG), Chlamydia trachomatis (CT), and syphilis infections, among others, were detected in China in 2020. ~35% of the new infections registered were CT, which is one of the world’s most commonly reported sexually transmitted infections (STIs). According to the WHO, by the 27th week of 2023, ~4,250 people were tested positive for influenza and nearly 23,300 specimens were processed for detection of influenza virus. This created a demand for molecular diagnostic products and services in Malaysia. Data published in the Korean Journal of Internal Medicine mentions that the incidence of TB in South Korea was 39 cases per 100,000 people in 2020. Moreover, the proportion of newly diagnosed cases of TB in elderly patients aged over 65 years has increased considerably from 27.5% (in 2008) to 48.5% (2020). According to the World Health Organization, Indonesia recorded 200 cases of human infection with the avian influenza A (H5N1) virus in January 2020. Out of these, 168 cases were fatal and resulted in an 84% mortality rate (168/200), which is much higher than the global fatality rate of 53%. Molecular diagnostic tools such as polymerase chain reaction (PCR), sequencing, hybridization, and microarray are employed for the detection of these infectious diseases as they surface as rapid and sensitive approaches for screening, detection, and monitoring.
Asia Pacific Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Molecular Diagnostics for Infectious Disease Market Segmentation
The Asia Pacific molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.
Based on type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Asia Pacific molecular diagnostics market for infectious disease market share in 2022.
The Asia Pacific molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Asia Pacific molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Asia Pacific molecular diagnostics market for infectious disease market share in 2022.
Based on application, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022.
Based on disease type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022.
Based on infection type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022.
Based on country, the Asia Pacific molecular diagnostics for infectious disease market is categorized into Malaysia, India, Indonesia, China, Japan, South Korea, and the Rest of Asia Pacific. The Rest of Asia Pacific dominated the Asia Pacific molecular diagnostics for infectious disease market in 2022.
Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific molecular diagnostics for infectious disease market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Asia Pacific molecular diagnostics for infectious disease market was valued at US$ 834.22 million in 2022 and is expected to reach US$ 2,360.34 million by 2030, registering a CAGR of 13.9% from 2022 to 2030. Rising application of molecular diagnostics in veterinary infectious diseases and surging prevalence of infectious disease globally are among the critical factors attributed to the Asia Pacific molecular diagnostics for infectious disease market expansion.
Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential for reducing economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally for detecting animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, highly sensitive, and specific, with the ability to detect at a high volume.
Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating swine fever virus, avian influenza virus, classical swine fever virus, and foot-and-mouth disease virus for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR.
Thus, molecular diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals can replace the conventional methods such as serological, microscopic, and culture-based techniques.
On the contrary, limitations associated with molecular testing hampers the growth Asia Pacific molecular diagnostics for infectious disease market.
Based on type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 62.6% share of Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 521.89 million. It is projected to garner US$ 1,446.98 million by 2030 to expand at 13.6% CAGR during 2022-2030.
The Asia Pacific molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 94.5% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 295.15 million. It is projected to garner US$ 858.67 million by 2030 to expand at 14.3% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 94.4% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 492.86 million. It is projected to garner US$ 1,359.15 million by 2030 to expand at 13.5% CAGR during 2022-2030.
Based on application, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 45.8% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 142.98 million. It is projected to garner US$ 408.80 million by 2030 to expand at 14.0% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 36.6% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 191.02 million. It is projected to garner US$ 527.28 million by 2030 to expand at 13.5% CAGR during 2022-2030.
Based on disease type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 64.7% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 202.16 million. It is projected to garner US$ 601.54 million by 2030 to expand at 14.6% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 53.3% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 278.10 million. It is projected to garner US$ 785.00 million by 2030 to expand at 13.9% CAGR during 2022-2030.
Based on infection type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 48.2% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 150.41 million. It is projected to garner US$ 431.68 million by 2030 to expand at 14.1% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 47.8% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 249.51 million. It is projected to garner US$ 678.94 million by 2030 to expand at 13.3% CAGR during 2022-2030.
Based on country, the Asia Pacific molecular diagnostics for infectious disease market is categorized into Malaysia, India, Indonesia, China, Japan, South Korea, and the Rest of Asia Pacific. The Rest of Asia Pacific held 27.8% share of Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 231.66 million. It is projected to garner US$ 672.46 million by 2030 to expand at 14.2% CAGR during 2022-2030.
Key players operating in the Asia Pacific molecular diagnostics for infectious disease market are Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.
In Dec 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
In Feb 2023, Thermo Fisher Scientific launched PCR kits for infectious disease detection in India. Thermo Fisher Scientific announced that its Applied Biosystems TaqPath PCR kits for infectious diseases such as multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO) and will be manufactured in India in association with Mylab Discovery Solutions.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific molecular diagnostics for infectious disease market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the molecular diagnostics for infectious disease market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Surging Prevalence of Infectious Disease Globally
4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:
5. Molecular Diagnostic for Infectious Diseases Market – Asia Pacific Market Analysis
5.1 Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
6. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
6.3.1 Overview
6.3.2 Point-of-Care Testing: Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
6.4.1 Overview
6.4.2 Laboratory Testing: Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by End User
7.1 Overview
7.1.1 Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
7.1.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
7.1.3 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
8. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
8.3.1 Overview
8.3.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
8.4 Laboratory Testing
8.4.1 Overview
8.4.2 Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
9. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Disease Type
9.1 Overview
9.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
9.3.2.1 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
9.4.2.1 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
10. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Infection Type
10.1 Overview
10.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Country Analysis
11.1 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.2 Asia Pacific Molecular Diagnostic for Infectious Diseases Market, by Country
11.1.2.1 China
11.1.2.1.1 China Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1.2 China: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.1.3 China: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.1.4 China: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.1.5 China: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.1.6 China: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.1.7 China: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.1.7.1 China: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.1.8 China: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.1.8.1 China: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.1.9 China: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.1.10 China: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.2 Japan
11.1.2.2.1 Japan Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.2.2 Japan: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.2.3 Japan: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.2.4 Japan: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.2.5 Japan: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.2.6 Japan: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.2.7 Japan: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.2.7.1 Japan: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.2.8 Japan: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.2.8.1 Japan: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.2.9 Japan: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.2.10 Japan: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.3 India
11.1.2.3.1 India Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.3.2 India: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.3.3 India: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.3.4 India: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.3.5 India: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.3.6 India: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.3.7 India: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.3.7.1 India: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.3.8 India: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.3.8.1 India: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.3.9 India: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.3.10 India: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.4 South Korea
11.1.2.4.1 South Korea Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.4.2 South Korea: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.4.3 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.4.4 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.4.5 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.4.6 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.4.7 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.4.7.1 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.4.8 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.4.8.1 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.4.9 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.4.10 South Korea: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.5 Malaysia
11.1.2.5.1 Malaysia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.5.2 Malaysia: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.5.3 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.5.4 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.5.5 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.5.6 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.5.7 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.5.7.1 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.5.8 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.5.8.1 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.5.9 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.5.10 Malaysia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.6 Indonesia
11.1.2.6.1 Indonesia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.6.2 Indonesia: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.6.3 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.6.4 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.6.5 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.6.6 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.6.7 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.6.7.1 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.6.8 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.6.8.1 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.6.9 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.6.10 Indonesia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.7 Rest of Asia Pacific
11.1.2.7.1 Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.7.2 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.7.3 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.7.4 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.7.5 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.7.6 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.7.7 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.7.7.1 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.7.8 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.7.8.1 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.7.9 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.7.10 Rest of Asia Pacific: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Abbott Laboratories
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 bioMerieux SA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Danaher Corp
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Hologic Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens Healthineers AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bruker Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 DiaSorin SpA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Segmentation
Table 2. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 4. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 8. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 10. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 11. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. China Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. China Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. China Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. China Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 16. China Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. China Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. China Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 19. China Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. China Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 21. China Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 22. China Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Japan Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. Japan Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Japan Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 26. Japan Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 27. Japan Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 28. Japan Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. Japan Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 30. Japan Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 31. Japan Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 32. Japan Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. Japan Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 34. India Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 35. India Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 36. India Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. India Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 38. India Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 39. India Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. India Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 41. India Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 42. India Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 43. India Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. India Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 45. South Korea Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 46. South Korea Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 47. South Korea Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 48. South Korea Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 49. South Korea Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 50. South Korea Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 51. South Korea Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 52. South Korea Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 53. South Korea Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 54. South Korea Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 55. South Korea Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. Malaysia Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 57. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 58. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 60. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 61. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 62. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 63. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 64. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 65. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 66. Malaysia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 67. Indonesia Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 68. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 69. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 70. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 71. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 72. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 73. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 74. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 75. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 76. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 77. Indonesia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 78. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 79. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 80. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 81. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 82. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 83. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 84. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 85. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 86. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 87. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 88. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 89. Organic Developments Done By Companies
Table 90. Inorganic Developments Done By Companies
Table 91. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market
LIST OF FIGURES
Figure 1. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
Figure 2. Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 6. Point-of-Testing: Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Laboratory Testing: Asia Pacific Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 10. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 11. Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 12. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 13. Asia Pacific Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 14. China Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 15. Japan Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. India Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. South Korea Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Malaysia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Indonesia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Rest of Asia Pacific Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – Asia Pacific Molecular Diagnostics for Infectious Disease Market
1. Abbott Laboratories
2. bioMerieux SA
3. Bruker Corp
4. Danaher Corp
5. DiaSorin SpA
6. F. Hoffmann-La Roche Ltd
7. Hologic Inc
8. Siemens Healthineers AG
9. Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.